• Vol. 44 No. 10, 434–439
  • 15 October 2015

Singapore Cancer Network (SCAN) Guidelines for the Systemic Therapy of Endometrial (Uterine) Cancer



Introduction: The SCAN gynaecological cancers systemic therapy workgroup aimed to develop Singapore Cancer Network (SCAN) clinical practice guidelines for the systemic therapy of endometrial (uterine) cancer.

Materials and Methods: The workgroup utilised a modified ADAPTE process to calibrate high quality international evidence-based clinical practice guidelines to our local setting.

Results: Three international guidelines were evaluated—those developed by the National Cancer Comprehensive Network (2015), the European Society of Medical Oncology (2013) and the Cancer Council Australia (2011). Recommendations on the role of chemotherapy following surgery in women diagnosed with endometrial cancer, the chemotherapeutic options for women with advanced or recurrent endometrial cancers and the role of chemotherapy in women with uterine papillary serous carcinoma or clear cell carcinoma were developed.

Conclusion: These adapted guidelines form the SCAN Guidelines 2015 for the systemic therapy of endometrial (uterine) cancer.

Endometrial (uterine) cancer is the fourth most common cancer in women in Singapore and the most common cancer of the female genital tract. It accounts for 6.2% of all cancers in women. The age standardised incidence rate for endometrial cancer has increased significantly over the last 40 years from 4.1 per 100,000 in 1973 to 1977 to 13.1 per 100,000 in 2008 to 2012. Amongst the ethnic groups, the age standardised incidence rate was highest among the Indians. The Singapore cancer registry estimates there will be 350 new cases this year. Endometrial cancer which is usually diagnosed in early stage has a high curative rate. Despite the rising incidence, endometrial cancer is associated with a lower mortality, and is the eleventh most common cause of cancer death in females in Singapore. There were 203 deaths from endometrial cancer for the period 2008 to 2012. The majority of cases diagnosed are in women under the age of 50 years. The peak age at diagnosis is 50 to 59 years of age. The majority of cases are stage I cancers.

This article is available only as a PDF. Please click on “Download PDF” on top to view the full article.